Sitagliptin Phosphate + Metformin HCL
The combination of Sitagliptin Phosphate and Metformin HCL is widely used in the management of type 2 diabetes mellitus. Sitagliptin is a DPP-4 inhibitor that enhances the body’s natural ability to regulate blood sugar by increasing insulin release and decreasing glucagon levels. Metformin is a biguanide that works by reducing hepatic glucose production and improving insulin sensitivity. Together, they provide effective glycemic control.
- Recommended Usage
Indications:
- Management of type 2 diabetes mellitus in adults.
- As an adjunct to diet and exercise to improve glycemic control.
- May be used as monotherapy or in combination with other antidiabetic medications.
Dosage and Administration:
- Typically administered orally twice daily with meals to reduce gastrointestinal side effects.
- Dosage varies based on patient needs:
- Common doses: Sitagliptin 50mg + Metformin 500mg/850mg/1000mg.
- Adjustments may be made depending on renal function or glycemic control.
- Maximum daily dose should not exceed Sitagliptin 100mg and Metformin 2000mg.
Precautions:
- Contraindicated in patients with severe renal impairment, metabolic acidosis, or hypersensitivity to any component.
- Use with caution in elderly patients or those with liver disease.
- Discontinue immediately if lactic acidosis is suspected.
- Regular monitoring of renal function is recommended.
Key Benefits:
- Dual Action: Combines two complementary mechanisms to effectively manage blood glucose levels.
- Improved Glycemic Control: Helps reduce both fasting and postprandial blood glucose.
- Weight Neutral: Unlike other diabetes medications, this combination is generally weight neutral.
- Convenience: Simplifies treatment with a single tablet regimen.
